The impact of the large B-cell lymphoma tumor microenvironment on efficacy of CD19-directed CAR-T immunotherapy
-
By
-
Helen P. Cashman
-
Cameron J. Turtle
-
June 24, 2026
-
Clinical Scorecard: Influence of the Tumor Microenvironment in Large B-Cell Lymphoma on the Effectiveness of CD19-Targeted CAR-T Therapy
At a Glance
| Category | Detail |
|---|
| Condition | Large B-cell lymphoma |
| Key Mechanisms | Tumor microenvironment influences treatment resistance and clinical responses to CD19 CAR-T therapy. |
| Target Population | Patients with relapsed or refractory large B-cell lymphoma. |
| Care Setting | Oncology and hematology clinics administering CAR-T therapy. |
Key Highlights
- Over half of patients do not achieve durable remissions with CD19 CAR-T therapy.
- Tumor microenvironment features significantly impact treatment outcomes.
- Emerging CAR-T engineering strategies aim to overcome immunosuppressive elements.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of large B-cell lymphoma includes histological and molecular characterization.
Management
- CD19-directed CAR-T therapy is a key treatment for relapsed or refractory large B-cell lymphoma.
Monitoring & Follow-up
- Monitor for immune-mediated adverse events such as cytokine release syndrome and neurotoxicity.
Risks
- Risks include treatment resistance due to tumor microenvironment factors and adverse effects from CAR-T therapy.
Patient & Prescribing Data
Patients with relapsed or refractory large B-cell lymphoma.
Understanding the tumor microenvironment is crucial for improving CAR-T therapy outcomes.
Clinical Best Practices
- Utilize advanced analytical approaches to characterize the tumor microenvironment.
- Consider patient and disease characteristics when evaluating CAR-T therapy efficacy.
Related Resources & Content
